TRIUMEQ TABLETS PATIENT ALERT CARD

SIDE 1

IMPORTANT - PATIENT ALERT CARD
Triumeq (dolutegravir / abacavir / lamivudine) tablets
Carry this card with you at all times

Since Triumeq contains abacavir some patients taking Triumeq may develop a hypersensitivity reaction (serious allergic reaction). This reaction **can be life-threatening** if treatment with Triumeq is continued. **CONTACT YOUR DOCTOR IMMEDIATELY for advice on whether you should stop taking Triumeq if:**

1) you get a skin rash OR
2) you get one or more symptoms from at least TWO of the following groups

- fever
- shortness of breath, sore throat or cough
- nausea or vomiting or diarrhoea or abdominal pain
- severe tiredness or achiness or generally feeling ill

If you have discontinued Triumeq due to this reaction, **YOU MUST NEVER TAKE** Triumeq, or any medicine containing abacavir again as **within hours** you may experience a life-threatening lowering of your blood pressure or death.

(see reverse of card)

Approval date: September 2022 NX-MT-DAL-CRD-220001

SIDE 2

You should immediately contact your doctor if you think you are having a hypersensitivity reaction to Triumeq. Write your doctor's details below:

Doctor:.....…… Tel:.....……

If your doctor is not available, you must urgently seek alternative medical advice (e.g. the emergency unit of the nearest hospital).

For general Triumeq information enquiries, contact:
ViiV Healthcare BV
Tel: + 356 80065004

Reporting of suspected adverse reactions
Suspected Adverse Drug Reactions (side effects) or medication errors may be reported using the Medicines Authority ADR reporting form, which is available online at http://www.medicinesauthority.gov.mt/adrportal, and sent by post or email to;
P: Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN 3000
E: postlicensing.medicinesauthority@gov.mt
Alternatively such events may also be reported to ViiV Healthcare BV on + 356 80065004 or mt.safety@gsk.com.

Approval date: September 2022 NX-MT-DAL-CRD-220001